Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Sees Large Drop in Short Interest

Key Points

• Short interest in Chugai Pharmaceutical Co., Ltd. declined by 78.1% in August, with total short interest dropping to 24,300 shares from 110,900 shares in July.
• The stock price of Chugai Pharmaceutical decreased by 0.5%, opening at $21.79, with a twelve-month market cap of $71.71 billion.
• For the last quarter, Chugai Pharmaceutical reported $0.20 earnings per share and revenues of $2.01 billion, with analysts expecting earnings per share of $0.74 for the current year.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) was the target of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totaling 24,300 shares, adecreaseof78.1% from the July 31st total of 110,900 shares. Based on an average trading volume of 271,000 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 271,000 shares, the days-to-cover ratio is currently 0.1 days.

Chugai Pharmaceutical Price Performance

Shares of CHGCY traded up $0.06 during midday trading on Friday, hitting $22.25. The stock had a trading volume of 120,486 shares, compared to its average volume of 236,239. Chugai Pharmaceutical has a 1 year low of $19.50 and a 1 year high of $31.26. The firm has a market cap of $73.23 billion, a PE ratio of 28.16 and a beta of 0.65. The stock's 50 day moving average is $22.92 and its 200 day moving average is $24.56.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its earnings results on Thursday, July 24th. The company reported $0.20 earnings per share for the quarter. The business had revenue of $2.01 billion for the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. As a group, equities research analysts expect that Chugai Pharmaceutical will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.